Material: Moxiflacin 0.5% eye drops: per ml There are 5 mg of moxifloxacin Equvalent to the moxifloxacin hydrochloride INN
Instructions: 0.5% of eyesight in moxifloxacin is indicated by congenital inflammation caused by the following germs: Aroobic Village-Positive Germs: Cinebacterium Species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus eipardimidis, Staphylococcus hemolyticus, Staphylococcus hominis, Staphylococcus warrior, Streptococcus pneumonee, St. Raptococcus videadens group Aroobic Village-Negative Bacteria: Acetateobacter lupine, Hypophilus influenza, Hypophilus paras Influenza Other bacteria: Chlamydia trachamatis
Dimensions and Usage Rules: Apply one drops in the infected eyes 3 times a day. Duration of treatment: 7 days.
In cases where it can not be used: These medicines can not be used for sensitive patients against moxifloxacin, other quinolones and other substances of this drug.
Use during pregnancy and breastfeeding: Since this drug is not available in pregnancy, it is necessary to apply the medicines considering the risk of fetal and the benefit of the patient. It has not been tested whether humans are immunized in the milk of moxifloxacin.
Side effects: Commonly seen side effects include conjunctive inflammation, reducing visceral vision, eye dryness, corneal inflammation, perspiration in the eyes, hypermia, pain, itching, subcutaneous bleeding and watering through the eyes. These side effects are seen in patients from 1 to 6% of patients. Other side effects are fever, cough increase, mediate inflammation, infection of the germs caused by infection, inflammation of the fumes, rashes and rhinitis. These side effects can be found in 1-4% of patients.
āĻāĻĒাāĻĻাāύ : āĻŽāĻ্āϏিāĻĢ্āϞāĻ্āϏাāϏিāύ ā§Ļ.ā§Ģ% āĻোāĻেāϰ āĻĄ্āϰāĻĒāϏ্: āĻĒ্āϰāϤি āĻŽি.āϞি. āĻ āĻāĻে āĻŽāĻ্āϏিāĻĢ্āϞāĻ্āϏাāϏিāύ ā§Ģ āĻŽি.āĻ্āϰা. āĻāϰ āϏāĻŽāϤুāϞ্āϝ āĻŽāĻ্āϏিāĻĢ্āϞāĻ্āϏাāϏিāύ āĻšাāĻāĻĄ্āϰোāĻ্āϞোāϰাāĻāĻĄ āĻāĻāĻāύāĻāύ।
āύিāϰ্āĻĻেāĻļāύা : āĻŽāĻ্āϏিāĻĢ্āϞāĻ্āϏাāϏিāύ ā§Ļ.ā§Ģ% āĻোāĻেāϰ āĻĄ্āϰāĻĒāϏ্ āύিāĻŽ্āύāϞিāĻিāϤ āĻীāĻŦাāĻŖু āĻĻ্āĻŦাāϰা āϏৃāώ্āĻ āĻāύāĻাংāĻিāĻাāϰ āĻĒ্āϰāĻĻাāĻšে āύিāϰ্āĻĻেāĻļিāϤ: āĻāϰোāĻŦিāĻ āĻ্āϰাāĻŽ-āĻĒāĻিāĻিāĻ āĻীāĻŦাāĻŖু: āĻāϰিāύেāĻŦ্āϝাāĻāĻেāϰিāϝ়াāĻŽ āϏ্āĻĒিāϏিāĻ, āĻŽাāĻāĻ্āϰোāĻāĻ্āĻাāϏ āϞুāĻিāϝ়াāϏ, āϏ্āĻ্āϝাāĻĢাāĻāϞোāĻāĻ্āĻাāϏ āĻ āϰিāϝ়াāϏ, āϏ্āĻ্āϝাāĻĢাāĻāϞোāĻāĻ্āĻাāϏ āĻāĻĒিāĻĄাāϰāĻŽিāĻĄিāϏ, āϏ্āĻ্āϝাāĻĢাāĻāϞোāĻāĻ্āĻাāϏ āĻšেāĻŽোāϞাāĻāĻিāĻাāϏ, āϏ্āĻ্āϝাāĻĢাāĻāϞোāĻāĻ্āĻাāϏ āĻšোāĻŽিāύিāϏ, āϏ্āĻ্āϝাāĻĢাāĻāϞোāĻāĻ্āĻাāϏ āĻāϝ়াāϰāύাāϰি, āϏ্āĻ্āϰেāĻĒāĻোāĻāĻ্āĻাāϏ āύিāĻāĻŽোāύি, āϏ্āĻ্āϰেāĻĒāĻোāĻāĻ্āĻাāϏ āĻিāϰিāĻĄ্āϝাāύ্āϏ āĻ্āϰুāĻĒ āĻāϰোāĻŦিāĻ āĻ্āϰাāĻŽ-āύেāĻেāĻিāĻ āĻীāĻŦাāĻŖু: āĻ্āϝাāϏিāύেāĻোāĻŦ্āϝাāĻāĻাāϰ āϞোāĻĢি, āĻšিāĻŽোāĻĢিāϞাāϏ āĻāύāĻĢ্āϞুāϝ়েāĻ্āĻা, āĻšিāĻŽোāĻĢিāϞাāϏ āĻĒ্āϝাāϰা āĻāύāĻĢ্āϞুāϝ়েāĻ্āĻা āĻ āύ্āϝাāύ্āϝ āĻীāĻŦাāĻŖু: āĻ্āϞ্āϝাāĻŽাāĻāĻĄিāϝ়া āĻ্āϰ্āϝাāĻোāĻŽাāĻিāϏ
āĻŽাāϤ্āϰা āĻ āĻŦ্āϝāĻŦāĻšাāϰ āĻŦিāϧি : āĻāĻ্āϰাāύ্āϤ āĻোāĻে āĻāĻ āĻĢোঁāĻা āĻāϰে āĻĻিāύে ā§Š āĻŦাāϰ āĻĒ্āϰāϝ়োāĻ āĻāϰāϤে āĻšāĻŦে। āĻিāĻিā§āϏাāϰ āϏāĻŽāϝ়āĻাāϞ: ā§ āĻĻিāύ।
āϝেāϏāĻŦ āĻ্āώেāϤ্āϰে āĻŦ্āϝāĻŦāĻšাāϰ āĻāϰা āϝাāĻŦে āύা : āĻŽāĻ্āϏিāĻĢ্āϞāĻ্āϏাāϏিāύ, āĻ āύ্āϝাāύ্āϝ āĻুāĻāύোāϞোāύ āĻāĻŦং āĻāĻ āĻāώুāϧেāϰ āĻ āύ্āϝাāύ্āϝ āĻāĻĒাāĻĻাāύেāϰ āĻĒ্āϰāϤি āϏংāĻŦেāĻĻāύāĻļীāϞ āϰোāĻীāĻĻেāϰ āĻ্āώেāϤ্āϰে āĻāĻ āĻāώুāϧ āĻŦ্āϝāĻŦāĻšাāϰ āĻāϰা āϝাāĻŦে āύা।
āĻāϰ্āĻাāĻŦāϏ্āĻĨা āĻ āϏ্āϤāύ্āϝāĻĻাāύāĻাāϞে āĻŦ্āϝāĻŦāĻšাāϰ : āϝেāĻšেāϤু āĻāĻ āĻāώুāϧ āĻāϰ্āĻাāĻŦāϏ্āĻĨাāϝ় āĻŦ্āϝāĻŦāĻšাāϰেāϰ āĻ্āώেāϤ্āϰে āĻĒāϰ্āϝাāĻĒ্āϤ āϤāĻĨ্āϝ āĻĒাāĻāϝ়া āϝাāϝ়āύি āϤাāĻ āĻ্āϰুāĻŖেāϰ āĻুঁāĻি āĻ āϰোāĻীāϰ āĻāĻĒāĻাāϰেāϰ āĻāĻĨা āĻŦিāĻŦেāĻāύা āĻāϰে āĻāĻ āĻāώুāϧ āĻĒ্āϰāϝ়োāĻ āĻāϰা āĻāĻিāϤ। āĻŽাāύুāώেāϰ āĻĻুāϧে āĻŽāĻ্āϏিāĻĢ্āϞāĻ্āϏাāϏিāύ āύিঃāϏৃāϤ āĻšāϝ় āĻিāύা āϤা āĻĒāϰীāĻ্āώা āĻāϰে āĻĻেāĻা āĻšāϝ়āύি।
āĻĒাāϰ্āĻļ্āĻŦ āĻĒ্āϰāϤিāĻ্āϰিāϝ়া : āϏāĻāϰাāĻāϰ āĻĻেāĻা āϝাāϝ় āĻāĻŽāύ āĻোāĻেāϰ āĻĒাāϰ্āĻļ্āĻŦ āĻĒ্āϰāϤিāĻ্āϰিāϝ়াāĻুāϞোāϰ āĻŽāϧ্āϝে āϰāϝ়েāĻে āĻāύāĻাংāĻিāĻাāϰ āĻĒ্āϰāĻĻাāĻš, āĻĻৃāώ্āĻিāϰ āϤীāĻ্āώ্āĻŽāϤা āĻš্āϰাāϏ, āĻোāĻেāϰ āĻļুāώ্āĻāϤা, āĻāϰ্āĻŖিāϝ়াāϰ āĻĒ্āϰāĻĻাāĻš, āĻোāĻে āĻ āĻļ্āĻŦāϏ্āϤিāĻাāĻŦ, āĻšাāĻāĻĒাāϰেāĻŽিāϝ়া, āĻŦ্āϝāĻĨা, āĻুāϞāĻাāύি, āϏাāĻŦāĻāύāĻাংāĻিāĻাāϰ āϰāĻ্āϤāĻ্āώāϰāĻŖ āĻāĻŦং āĻোāĻ āĻĻিāϝ়ে āĻĒাāύি āĻĒāĻĄ়া। āĻāϏāĻŦ āĻĒাāϰ্āĻļ্āĻŦ āĻĒ্āϰāϤিāĻ্āϰিāϝ়াāĻুāϞো ā§§ āĻĨেāĻে ā§Ŧ% āϰোāĻীāϰ āĻ্āώেāϤ্āϰে āĻĻেāĻা āϝাāϝ়। āĻ āύ্āϝাāύ্āϝ āĻĒাāϰ্āĻļ্āĻŦ āĻĒ্āϰāϤিāĻ্āϰিāϝ়াāĻুāϞো āĻšāϞ āĻ্āĻŦāϰ, āĻাāĻļি āĻŦৃāĻĻ্āϧি āĻĒাāĻāϝ়া, āĻŽāϧ্āϝāĻāϰ্āĻŖে āĻĒ্āϰāĻĻাāĻš, āĻীāĻŦাāĻŖু āĻĻ্āĻŦাāϰা āϏৃāώ্āĻ āϰোāĻেāϰ āϏংāĻ্āϰāĻŽāĻŖ, āĻĢ্āϝাāϰিংāϏ্ āĻāϰ āĻĒ্āϰāĻĻাāĻš, āϰ্āϝাāĻļ āĻāĻŦং āϰাāĻāύাāĻāĻিāϏ। āĻāϏāĻŦ āĻĒাāϰ্āĻļ্āĻŦ āĻĒ্āϰāϤিāĻ্āϰিāϝ়াāĻুāϞো ā§§-ā§Ē% āϰোāĻীāϰ āĻ্āώেāϤ্āϰে āĻĻেāĻা āϝাāϝ়।
Instructions: 0.5% of eyesight in moxifloxacin is indicated by congenital inflammation caused by the following germs: Aroobic Village-Positive Germs: Cinebacterium Species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus eipardimidis, Staphylococcus hemolyticus, Staphylococcus hominis, Staphylococcus warrior, Streptococcus pneumonee, St. Raptococcus videadens group Aroobic Village-Negative Bacteria: Acetateobacter lupine, Hypophilus influenza, Hypophilus paras Influenza Other bacteria: Chlamydia trachamatis
Dimensions and Usage Rules: Apply one drops in the infected eyes 3 times a day. Duration of treatment: 7 days.
In cases where it can not be used: These medicines can not be used for sensitive patients against moxifloxacin, other quinolones and other substances of this drug.
Use during pregnancy and breastfeeding: Since this drug is not available in pregnancy, it is necessary to apply the medicines considering the risk of fetal and the benefit of the patient. It has not been tested whether humans are immunized in the milk of moxifloxacin.
Side effects: Commonly seen side effects include conjunctive inflammation, reducing visceral vision, eye dryness, corneal inflammation, perspiration in the eyes, hypermia, pain, itching, subcutaneous bleeding and watering through the eyes. These side effects are seen in patients from 1 to 6% of patients. Other side effects are fever, cough increase, mediate inflammation, infection of the germs caused by infection, inflammation of the fumes, rashes and rhinitis. These side effects can be found in 1-4% of patients.
āĻāĻĒাāĻĻাāύ : āĻŽāĻ্āϏিāĻĢ্āϞāĻ্āϏাāϏিāύ ā§Ļ.ā§Ģ% āĻোāĻেāϰ āĻĄ্āϰāĻĒāϏ্: āĻĒ্āϰāϤি āĻŽি.āϞি. āĻ āĻāĻে āĻŽāĻ্āϏিāĻĢ্āϞāĻ্āϏাāϏিāύ ā§Ģ āĻŽি.āĻ্āϰা. āĻāϰ āϏāĻŽāϤুāϞ্āϝ āĻŽāĻ্āϏিāĻĢ্āϞāĻ্āϏাāϏিāύ āĻšাāĻāĻĄ্āϰোāĻ্āϞোāϰাāĻāĻĄ āĻāĻāĻāύāĻāύ।
āύিāϰ্āĻĻেāĻļāύা : āĻŽāĻ্āϏিāĻĢ্āϞāĻ্āϏাāϏিāύ ā§Ļ.ā§Ģ% āĻোāĻেāϰ āĻĄ্āϰāĻĒāϏ্ āύিāĻŽ্āύāϞিāĻিāϤ āĻীāĻŦাāĻŖু āĻĻ্āĻŦাāϰা āϏৃāώ্āĻ āĻāύāĻাংāĻিāĻাāϰ āĻĒ্āϰāĻĻাāĻšে āύিāϰ্āĻĻেāĻļিāϤ: āĻāϰোāĻŦিāĻ āĻ্āϰাāĻŽ-āĻĒāĻিāĻিāĻ āĻীāĻŦাāĻŖু: āĻāϰিāύেāĻŦ্āϝাāĻāĻেāϰিāϝ়াāĻŽ āϏ্āĻĒিāϏিāĻ, āĻŽাāĻāĻ্āϰোāĻāĻ্āĻাāϏ āϞুāĻিāϝ়াāϏ, āϏ্āĻ্āϝাāĻĢাāĻāϞোāĻāĻ্āĻাāϏ āĻ āϰিāϝ়াāϏ, āϏ্āĻ্āϝাāĻĢাāĻāϞোāĻāĻ্āĻাāϏ āĻāĻĒিāĻĄাāϰāĻŽিāĻĄিāϏ, āϏ্āĻ্āϝাāĻĢাāĻāϞোāĻāĻ্āĻাāϏ āĻšেāĻŽোāϞাāĻāĻিāĻাāϏ, āϏ্āĻ্āϝাāĻĢাāĻāϞোāĻāĻ্āĻাāϏ āĻšোāĻŽিāύিāϏ, āϏ্āĻ্āϝাāĻĢাāĻāϞোāĻāĻ্āĻাāϏ āĻāϝ়াāϰāύাāϰি, āϏ্āĻ্āϰেāĻĒāĻোāĻāĻ্āĻাāϏ āύিāĻāĻŽোāύি, āϏ্āĻ্āϰেāĻĒāĻোāĻāĻ্āĻাāϏ āĻিāϰিāĻĄ্āϝাāύ্āϏ āĻ্āϰুāĻĒ āĻāϰোāĻŦিāĻ āĻ্āϰাāĻŽ-āύেāĻেāĻিāĻ āĻীāĻŦাāĻŖু: āĻ্āϝাāϏিāύেāĻোāĻŦ্āϝাāĻāĻাāϰ āϞোāĻĢি, āĻšিāĻŽোāĻĢিāϞাāϏ āĻāύāĻĢ্āϞুāϝ়েāĻ্āĻা, āĻšিāĻŽোāĻĢিāϞাāϏ āĻĒ্āϝাāϰা āĻāύāĻĢ্āϞুāϝ়েāĻ্āĻা āĻ āύ্āϝাāύ্āϝ āĻীāĻŦাāĻŖু: āĻ্āϞ্āϝাāĻŽাāĻāĻĄিāϝ়া āĻ্āϰ্āϝাāĻোāĻŽাāĻিāϏ
āĻŽাāϤ্āϰা āĻ āĻŦ্āϝāĻŦāĻšাāϰ āĻŦিāϧি : āĻāĻ্āϰাāύ্āϤ āĻোāĻে āĻāĻ āĻĢোঁāĻা āĻāϰে āĻĻিāύে ā§Š āĻŦাāϰ āĻĒ্āϰāϝ়োāĻ āĻāϰāϤে āĻšāĻŦে। āĻিāĻিā§āϏাāϰ āϏāĻŽāϝ়āĻাāϞ: ā§ āĻĻিāύ।
āϝেāϏāĻŦ āĻ্āώেāϤ্āϰে āĻŦ্āϝāĻŦāĻšাāϰ āĻāϰা āϝাāĻŦে āύা : āĻŽāĻ্āϏিāĻĢ্āϞāĻ্āϏাāϏিāύ, āĻ āύ্āϝাāύ্āϝ āĻুāĻāύোāϞোāύ āĻāĻŦং āĻāĻ āĻāώুāϧেāϰ āĻ āύ্āϝাāύ্āϝ āĻāĻĒাāĻĻাāύেāϰ āĻĒ্āϰāϤি āϏংāĻŦেāĻĻāύāĻļীāϞ āϰোāĻীāĻĻেāϰ āĻ্āώেāϤ্āϰে āĻāĻ āĻāώুāϧ āĻŦ্āϝāĻŦāĻšাāϰ āĻāϰা āϝাāĻŦে āύা।
āĻāϰ্āĻাāĻŦāϏ্āĻĨা āĻ āϏ্āϤāύ্āϝāĻĻাāύāĻাāϞে āĻŦ্āϝāĻŦāĻšাāϰ : āϝেāĻšেāϤু āĻāĻ āĻāώুāϧ āĻāϰ্āĻাāĻŦāϏ্āĻĨাāϝ় āĻŦ্āϝāĻŦāĻšাāϰেāϰ āĻ্āώেāϤ্āϰে āĻĒāϰ্āϝাāĻĒ্āϤ āϤāĻĨ্āϝ āĻĒাāĻāϝ়া āϝাāϝ়āύি āϤাāĻ āĻ্āϰুāĻŖেāϰ āĻুঁāĻি āĻ āϰোāĻীāϰ āĻāĻĒāĻাāϰেāϰ āĻāĻĨা āĻŦিāĻŦেāĻāύা āĻāϰে āĻāĻ āĻāώুāϧ āĻĒ্āϰāϝ়োāĻ āĻāϰা āĻāĻিāϤ। āĻŽাāύুāώেāϰ āĻĻুāϧে āĻŽāĻ্āϏিāĻĢ্āϞāĻ্āϏাāϏিāύ āύিঃāϏৃāϤ āĻšāϝ় āĻিāύা āϤা āĻĒāϰীāĻ্āώা āĻāϰে āĻĻেāĻা āĻšāϝ়āύি।
āĻĒাāϰ্āĻļ্āĻŦ āĻĒ্āϰāϤিāĻ্āϰিāϝ়া : āϏāĻāϰাāĻāϰ āĻĻেāĻা āϝাāϝ় āĻāĻŽāύ āĻোāĻেāϰ āĻĒাāϰ্āĻļ্āĻŦ āĻĒ্āϰāϤিāĻ্āϰিāϝ়াāĻুāϞোāϰ āĻŽāϧ্āϝে āϰāϝ়েāĻে āĻāύāĻাংāĻিāĻাāϰ āĻĒ্āϰāĻĻাāĻš, āĻĻৃāώ্āĻিāϰ āϤীāĻ্āώ্āĻŽāϤা āĻš্āϰাāϏ, āĻোāĻেāϰ āĻļুāώ্āĻāϤা, āĻāϰ্āĻŖিāϝ়াāϰ āĻĒ্āϰāĻĻাāĻš, āĻোāĻে āĻ āĻļ্āĻŦāϏ্āϤিāĻাāĻŦ, āĻšাāĻāĻĒাāϰেāĻŽিāϝ়া, āĻŦ্āϝāĻĨা, āĻুāϞāĻাāύি, āϏাāĻŦāĻāύāĻাংāĻিāĻাāϰ āϰāĻ্āϤāĻ্āώāϰāĻŖ āĻāĻŦং āĻোāĻ āĻĻিāϝ়ে āĻĒাāύি āĻĒāĻĄ়া। āĻāϏāĻŦ āĻĒাāϰ্āĻļ্āĻŦ āĻĒ্āϰāϤিāĻ্āϰিāϝ়াāĻুāϞো ā§§ āĻĨেāĻে ā§Ŧ% āϰোāĻীāϰ āĻ্āώেāϤ্āϰে āĻĻেāĻা āϝাāϝ়। āĻ āύ্āϝাāύ্āϝ āĻĒাāϰ্āĻļ্āĻŦ āĻĒ্āϰāϤিāĻ্āϰিāϝ়াāĻুāϞো āĻšāϞ āĻ্āĻŦāϰ, āĻাāĻļি āĻŦৃāĻĻ্āϧি āĻĒাāĻāϝ়া, āĻŽāϧ্āϝāĻāϰ্āĻŖে āĻĒ্āϰāĻĻাāĻš, āĻীāĻŦাāĻŖু āĻĻ্āĻŦাāϰা āϏৃāώ্āĻ āϰোāĻেāϰ āϏংāĻ্āϰāĻŽāĻŖ, āĻĢ্āϝাāϰিংāϏ্ āĻāϰ āĻĒ্āϰāĻĻাāĻš, āϰ্āϝাāĻļ āĻāĻŦং āϰাāĻāύাāĻāĻিāϏ। āĻāϏāĻŦ āĻĒাāϰ্āĻļ্āĻŦ āĻĒ্āϰāϤিāĻ্āϰিāϝ়াāĻুāϞো ā§§-ā§Ē% āϰোāĻীāϰ āĻ্āώেāϤ্āϰে āĻĻেāĻা āϝাāϝ়।
Tags:
Medicine